Clever Culture Systems Limited (CC5.AX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in AUD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | AUD m | - | 2 | 2 | 1 | 5 | - | 5 | 2 |
| Operating profit | AUD m | -1 | -4 | ||||||
| Net profit | AUD m | - | -7 | -23 | -4 | 2 | - | -2 | -1 |
| EPS reported | AUD | 0.00 | 0.00 | ||||||
| Operating cashflow per share | AUD | 0.00 | -0.00 | ||||||
| Capex per share | AUD | 0.00 | 0.00 | ||||||
| FCF per share | AUD | -0.00 | -0.00 | ||||||
| Free cash flow | AUD m | -1 | -3 | ||||||
| Net debt | AUD m | -0 | 1 | ||||||
| Book value equity | AUD m | 6 | 8 | ||||||
| Book value per share | AUD | 0.00 | 0.00 | ||||||
| Number of shares | m | 2,105 | 2,179.62 | ||||||
| DPS (TTM paid) | AUD | 0.00 | 0.00 |
Financial summary
Financials in AUD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 20.00 | - | ||||||
| P/B LTM | x | 2.33 | 3.67 | ||||||
| P/S LTM | x | 2.41 | 5.98 | ||||||
| P/FCF LTM | x | -11.28 | -10.70 | ||||||
| EV/EBITDA LTM | x | 63.56 | -7.67 | ||||||
| EV/Sales LTM | x | 5.23 | 6.88 | ||||||
| Earnings Yield LTM | % | +5.00% | -7.33% | ||||||
| FCF Yield | % | -8.87% | -9.34% | ||||||
| Quality | |||||||||
| ROE | % | +29.83% | -28.81% | ||||||
| ROIC | % | +2.64% | -18.35% | ||||||
| Operating margin | % | -21.50% | -95.37% | ||||||
| Gross margin | % | +72.59% | -42.76% | ||||||
| FCF/Sales | % | -21.33% | -55.88% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | -100.00% | ||||||
| Sales Growth YoY | % | +334.79% | -15.42% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.53 | -0.87 | ||||||
| Net Debt/EBITDA | x | 4.32 | -0.35 | ||||||
| EBIT/Net interest | x | -14.68 | -23.68 | ||||||
| Net debt/market cap | % | +3.53% | +5.95% | ||||||
| Net debt/Equity | x | -0.05 | 0.17 | ||||||
| Gross debt/equity | x | 0.39 | 0.40 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Based in Adelaide, Australia, Clever Culture Systems Limited, established in 2004, focuses on the innovation, development, and market launch of advanced technological solutions for the medical industry. The company operates internationally, serving markets in Australia, the United States, Sweden, the United Kingdom, China, the Netherlands, and Germany. Its core offering is the Automated Plate Assessment System (APAS), which efficiently images, analyzes, and interprets microbiology culture plates, primarily assisting microbiology laboratories and the pharmaceutical manufacturing sector. The company's portfolio also includes Digital Microbiology and specialized APAS modules—artificial intelligence algorithms designed to enable digital reading of culture plates when integrated with the APAS Independence system. Additionally, Clever Culture Systems is advancing its APAS intelligent imaging technology for diverse applications, including urine screening, infection control testing, and assessing antimicrobial susceptibility. Formerly known as LBT Innovations Limited, the company adopted its current name in November 2024.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Clever Culture Systems Limited (CC5.AX)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Based in Adelaide, Australia, Clever Culture Systems Limited, established in 2004, focuses on the innovation, development, and market launch of advanced technological solutions for the medical industry. The company operates internationally, serving markets in Australia, the United States, Sweden, the United Kingdom, China, the Netherlands, and Germany. Its core offering is the Automated Plate Assessment System (APAS), which efficiently images, analyzes, and interprets microbiology culture plates, primarily assisting microbiology laboratories and the pharmaceutical manufacturing sector. The company's portfolio also includes Digital Microbiology and specialized APAS modules—artificial intelligence algorithms designed to enable digital reading of culture plates when integrated with the APAS Independence system. Additionally, Clever Culture Systems is advancing its APAS intelligent imaging technology for diverse applications, including urine screening, infection control testing, and assessing antimicrobial susceptibility. Formerly known as LBT Innovations Limited, the company adopted its current name in November 2024.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free